Literature DB >> 23174760

Vaccination with embryonic stem cells generates effective antitumor immunity against ovarian cancer.

Zujuan Zhang1, Xinhua Chen, Xiaohong Chang, Xue Ye, Yi Li, Heng Cui.   

Abstract

To date, only a few studies have suggested that human embryonic stem cells (hESCs) might effectively immunize against colon and lung cancer. The purpose of this study was to investigate the therapeutic potential of hESCs as a vaccine to induce widespread antitumor effects in different animal models and various types of cancer. C57BL/6 mice with ID8 ovarian cancer cell and Fischer 344 rats with NuTu-19 ovarian cancer cell models were used. Fifty-four mice were divided into six groups with nine mice in each group. Each mouse was immunized with pre-inactivated hESCs (H9) or mouse embryonic stem cells (mESCs; IVP-ES1) or ID8 or phosphate-buffered saline (PBS). Twenty-four rats were divided into four groups with six rats in each group, each rat immunized with pre-inactivated hESCs (H9) or NuTu-19 or PBS. After the vaccination, each mouse was challenged with live ID8 cells subcutaneously, and each rat was challenged with live NuTu-19 cells intraperitoneally. We discovered that vaccination of mice with the hESC line H9 and the mESC line IVP-ES1 generated consistent cellular and humoral immune responses against ID8 ovarian cancer. H9 and IVP-ES1 vaccinated mice obtained antitumor immune protection, and H9 vaccinated rats had the longest survival time and least distant metastases. No evidence of side-effects was observed. We also compared the immunogenicity against ovarian cancer between the hESC line, H9, and the mESC line, IVP-ES1, that derived from the inner cell mass in different species. We found that there were no significant differences between them. Furthermore, immunohistochemical staining revealed that several oncogenes and tumor suppressor genes, such as HER-2, C-myc, p53, and nm23, were expressed in H9, many of which were also shared by ovarian cancer. hESC vaccines can induce antitumor effects in two animal models and in ovarian cancer, indicating that the activity of the vaccine is universal, and, more importantly, it is safe.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23174760     DOI: 10.3892/ijmm.2012.1195

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  7 in total

Review 1.  Past, present and future targets for immunotherapy in ovarian cancer.

Authors:  Carlton L Schwab; Diana P English; Dana M Roque; Monica Pasternak; Alessandro D Santin
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

2.  Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.

Authors:  Thaïs Baert; Ann Vankerckhoven; Matteo Riva; Anaïs Van Hoylandt; Gitte Thirion; Gerhardt Holger; Thomas Mathivet; Ignace Vergote; An Coosemans
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

Review 3.  Pluripotent Stem Cells: Cancer Study, Therapy, and Vaccination.

Authors:  Mojgan Barati; Maryam Akhondi; Narges Sabahi Mousavi; Newsha Haghparast; Asma Ghodsi; Hossein Baharvand; Marzieh Ebrahimi; Seyedeh-Nafiseh Hassani
Journal:  Stem Cell Rev Rep       Date:  2021-06-11       Impact factor: 5.739

4.  Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine.

Authors:  Di Wu; Jing Wang; Yunlang Cai; Mulan Ren; Yuxia Zhang; Fangfang Shi; Fengshu Zhao; Xiangfeng He; Meng Pan; Chunguang Yan; Jun Dou
Journal:  J Ovarian Res       Date:  2015-10-24       Impact factor: 4.234

Review 5.  Recent technological advances in using mouse models to study ovarian cancer.

Authors:  Carrie Danielle House; Lidia Hernandez; Christina Messineo Annunziata
Journal:  Front Oncol       Date:  2014-02-13       Impact factor: 6.244

6.  Mechanism of inhibiting proliferation of hepatocellular carcinoma Hepa1-6 cells by embryonic stem cell-conditioned medium.

Authors:  Longqin Li; Yichao Zheng; Qi Zheng; Jiaji Jiang
Journal:  Exp Ther Med       Date:  2020-02-12       Impact factor: 2.447

7.  Evidence of Antitumor and Antimetastatic Potential of Induced Pluripotent Stem Cell-Based Vaccines in Cancer Immunotherapy.

Authors:  Masae Kishi; Afag Asgarova; Christophe Desterke; Diana Chaker; Jérôme Artus; Ali G Turhan; Annelise Bennaceur-Griscelli; Frank Griscelli
Journal:  Front Med (Lausanne)       Date:  2021-12-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.